Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]JT001 in Healthy Males
NCT05802810Phase 1Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of desidustat in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoints: Total radioactive recovery at 1 month, Cumulative excretion rate of total radioactive material in fecal matter at 1 month and 4 more. Started Mar 2023; status: completed.
02
Drugs
desidustat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05802810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802810.